10/26 Late treatment study
et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint)
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
RCT 70 ivermectin-doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment.The earlier ivermectin+doxycycline was administered, the higher rate of successful therapy.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Hashim et al., 10/26/2020, Single Blind Randomized Controlled Trial, Iraq, Middle East, preprint, 6 authors, dosage 200μg/kg days 1-2, some patients received a third dose on day 8.
risk of death, 66.7% lower, RR 0.33, p = 0.27, treatment 2 of 70 (2.9%), control 6 of 70 (8.6%), all patients.
risk of death, 91.7% lower, RR 0.08, p = 0.03, treatment 0 of 59 (0.0%), control 6 of 70 (8.6%), excluding critical patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
